1. Home
  2. VRAX vs AIMD Comparison

VRAX vs AIMD Comparison

Compare VRAX & AIMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Virax Biolabs Group Limited

VRAX

Virax Biolabs Group Limited

HOLD

Current Price

$2.93

Market Cap

2.3M

Sector

Health Care

ML Signal

HOLD

Logo Ainos Inc.

AIMD

Ainos Inc.

HOLD

Current Price

$1.38

Market Cap

11.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VRAX
AIMD
Founded
2013
1984
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.3M
11.5M
IPO Year
2021
2008

Fundamental Metrics

Financial Performance
Metric
VRAX
AIMD
Price
$2.93
$1.38
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$1.00
N/A
AVG Volume (30 Days)
467.0K
31.2K
Earning Date
06-12-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$124,157.00
Revenue This Year
$217,274.83
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
498.95
52 Week Low
$0.10
$1.26
52 Week High
$13.19
$4.44

Technical Indicators

Market Signals
Indicator
VRAX
AIMD
Relative Strength Index (RSI) N/A 42.08
Support Level N/A $1.33
Resistance Level N/A $1.65
Average True Range (ATR) 0.00 0.11
MACD 0.00 0.01
Stochastic Oscillator 0.00 13.64

Price Performance

Historical Comparison
VRAX
AIMD

About VRAX Virax Biolabs Group Limited

Virax Biolabs Group Ltd is a biotechnology company focused on the detection of immune responses and the development of immune profiling and in vitro diagnostic technologies for viral and immune-mediated diseases, with a current strategic focus on post-acute infection syndromes (PAIS) and related areas of chronic immune dysfunction. The company's principal development activities are centered on T cell-based in vitro diagnostics and immune profiling. The company's flagship product candidate, ViraxImmune, is an in-development T cell-based assay and immune profiling platform intended to support the assessment of immune dysfunction, initially in PAIS indications.

About AIMD Ainos Inc.

Ainos Inc is a dual-platform company advancing artificial intelligence based smelltech technologies and immune therapeutics. Its primary strategic focus is the commercialization of its proprietary scent digitization platform, AI Nose, while the company also continue to develop therapeutic assets based on its low-dose oral interferon program, VELDONA. Its core technology platform, AI Nose, is an AI-based electronic olfaction system that integrates gas sensor arrays with proprietary artificial intelligence models, which it refers to as a smell language model (SLM), to digitize scent and volatile organic compound (VOC) signals into Smell ID, a machine-readable data format.

Share on Social Networks: